Enanta Pharma (ENTA) Tops Q2 EPS by 10c, Misses on Revenue

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.06), $0.10 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $15.95 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• UBS Starts Kalyan Jewellers India Ltd (KALYANKJ:IN) at Buy
• HSBC Downgrades Iflytek Co Ltd (002230:CH) to Hold
• Roblox announces standalone apps, browser play, and creator wallet